Warning: The NCBI web site requires JavaScript to function. more...
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Markopoulos C, Dafni U, Misitzis J, Zobolas V, Tzoracoleftherakis E, Koukouras D, Xepapadakis G, Papadiamantis J, Venizelos B, Antonopoulou Z, Gogas H.
Breast Cancer Res. 2009;11(3):R35. Epub 2009 Jun 16.
Related citations
Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.
Markopoulos C, Chrissochou M, Michailidou A, Tzoracoleftherakis E, Xepapadakis G, Papadiamantis J, Misitzis J, Zobolas V, Bafaloukos D, Gogas H.
Anticancer Drugs. 2005 Sep;16(8):879-83.
The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H.
Breast Cancer Res Treat. 2005 Sep;93(1):61-6.
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R.
Ann Oncol. 2004 Feb;15(2):211-7.
Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.
Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G, Gogas H.
Ann Oncol. 2009 Jan;20(1):49-55. Epub 2008 Aug 4.
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y.
Ann Oncol. 2011 Aug;22(8):1777-82. Epub 2011 Feb 1.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M.
Clin Ther. 2007 Aug;29(8):1535-47. Review.
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA.
Ann Oncol. 2005 May;16(5):707-15. Epub 2005 Apr 7.
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S.
Br J Cancer. 2006 Jul 17;95(2):153-8.
The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
Montagnani A, Gonnelli S, Cadirni A, Caffarelli C, Del Santo K, Pieropan C, Campagna MS, Montomoli M, Petrioli R, Nuti R.
Eur J Intern Med. 2008 Dec;19(8):592-7. Epub 2008 Apr 1.
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P.
J Clin Oncol. 2008 Oct 20;26(30):4883-90. Epub 2008 Sep 15.
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.
Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E.
J Clin Oncol. 2006 Feb 20;24(6):910-7.
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.
Bertelli G, Hall E, Ireland E, Snowdon CF, Jassem J, Drosik K, Karnicka-Mlodkowska H, Coombes RC, Bliss JM.
Ann Oncol. 2010 Mar;21(3):498-505. Epub 2009 Aug 28.
Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED, Scott LJ.
Drugs. 2009;69(7):889-918. doi: 10.2165/00003495-200969070-00007. Review.
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT, Robert NJ.
MedGenMed. 2005 Aug 24;7(3):20. Review.
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR, Hutson PR, Havighurst TC, Cleary JF.
Clin Cancer Res. 2005 Feb 15;11(4):1500-3.
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group.
Lancet Oncol. 2007 Feb;8(2):119-27.
Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
Nabholtz JM, Gligorov J.
Drug Saf. 2006;29(9):785-801. Review. Erratum in: Drug Saf. 2007;30(3):201.
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A.
Ann Oncol. 2009 Jul;20(7):1203-9. Epub 2009 Feb 13.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on